Novo Nordisk A/S: CHMP recommends EU approval of Wegovy® 7.2 mg in a single-dose pen, providing up to 20.7% mean weight loss

CHMP Recommends EU Approval for Wegovy 7.2 mg Single-Dose Pen

Novo Nordisk announced that the Committee for Medicinal Products for Human Use (CHMP) under the European Medicines Agency (EMA) has issued a positive opinion for marketing authorization of Wegovy® 7.2 mg (semaglutide) in a single-dose pen for people with obesity. This formulation, already available in the US and UK, demonstrated significant weight loss in the STEP UP trials. Specifically, the STEP UP trial showed a 20.7% mean weight loss in participants with obesity, with approximately one-third achieving 25% or greater weight loss. Novo Nordisk anticipates launching the single-dose pen in the EU in Q3 2026.

• Regulatory Milestone: The Committee for Medicinal Products for Human Use (CHMP) under the European Medicines Agency (EMA) has adopted a positive opinion, recommending marketing authorisation for Wegovy® 7.2 mg in a convenient once-weekly single-dose pen for adults living with obesity in the EU. This recommendation paves the way for a new administration option for the high-dose formulation.
• Clinical Efficacy: The STEP UP trial program demonstrated robust efficacy for semaglutide 7.2 mg. In the 72-week STEP UP trial, participants with obesity achieved a mean weight loss of 20.7%, with a notable 31.2% of patients experiencing 25% or greater weight loss. For those with obesity and type 2 diabetes (STEP UP T2D trial), the mean weight loss was 14.1% over the same duration.
• Market Availability & Convenience: Wegovy® 7.2 mg in a single-dose pen is already approved and available in the US (marketed as Wegovy® HD) and the UK. Novo Nordisk expects to launch this new, easy-to-use pen formulation in the EU in Q3 2026, offering a more convenient option for patients compared to the current EU formulation which requires three 2.4 mg injections.

Wegovy 7.2 mg Single-Dose Pen: Efficacy and Safety from STEP UP

Recent comprehensive evaluations have demonstrated the efficacy and safety profiles of multiple obesity interventions across different therapeutic classes. The SURMOUNT studies evaluated tirzepatide, a dual GIP/GLP-1 receptor agonist administered once weekly at doses ranging from 5-15 mg, across 9 RCTs involving 7,111 participants. At medium-term follow-up (12-18 months), tirzepatide achieved a mean percentage weight reduction of 16.03% from baseline (95% CI -18.91 to -13.14), with dose-dependent effects ranging from 9 kg weight loss at 5 mg to 12 kg at 15 mg doses at 6 months. The intervention increased the proportion of participants achieving 5% weight reduction by 3.60-fold compared to placebo, while demonstrating little to no clinically important difference in major adverse cardiovascular events or mortality.

Contemporary network meta-analyses of semaglutide 2.4 mg subcutaneous administration, informed by six trials, consistently demonstrated 11.5-12.5 kg weight loss across multiple time points. Semaglutide emerged as one of the most effective pharmacological interventions alongside tirzepatide, though direct comparison studies revealed tirzepatide 15 mg outperformed semaglutide 2.4 mg, while lower tirzepatide doses (5-10 mg) showed comparable efficacy. Both agents were generally associated with increased safety concerns compared to placebo, particularly gastrointestinal adverse events, though serious adverse events remained comparable to control groups.

The GenOn Programme represents an innovative precision nutrition approach currently under investigation through an 18-week, 2×2 factorial randomized controlled trial in 120 adults. This study tests genetic risk-based interventions targeting specific obesity variants (FTO rs9939609 and rs1782313, MC4R rs1782313, LEP rs7799039) through either standard or satiety-focused dietary counseling with calorie-restricted meal plans. While efficacy and safety outcomes are pending, the protocol encompasses comprehensive assessments including weight loss, body composition, cardiometabolic markers, and metagenomics at baseline, week 12, and week 18, potentially advancing personalized obesity treatment strategies.

Addressing Key Challenges in Obesity Management with Enhanced Convenience

Current obesity management faces persistent systemic barriers alongside evolving treatment paradigms. While recent pharmacological advances have demonstrated unprecedented efficacy, significant challenges remain in accessibility, sustainability, and clinical implementation across healthcare systems.

• Healthcare delivery and reimbursement barriers create fundamental access issues, including uncertainty about which providers should prescribe obesity pharmacotherapy, inconsistent third-party reimbursement across Medicaid, Medicare, and commercial plans, and drug shortages compounded by high demand and direct-to-consumer marketing

• Treatment sustainability and adherence challenges persist as a critical limitation, with GLP-1-based agents and other pharmacotherapies requiring lifelong treatment to maintain benefits, patient adherence to recommended measures remaining below 50% for medium- and long-term treatment, and high relapse risk following lifestyle modifications alone

• Limited treatment algorithm effectiveness continues to constrain outcomes, as the current stepwise approach starting with lifestyle intervention has modest long-term efficacy, bariatric surgery remains reserved as a last option despite superior effectiveness, and pharmacotherapy often provides only moderate efficacy or requires high doses with unacceptable side effects

• Clinical implementation gaps affect treatment optimization, including the relative lack of effective options for early diagnosis and long-term management, insufficient coordination in multidisciplinary approaches, and limited integration of novel multi-agonist therapies into established care pathways

• Mechanistic and safety uncertainties hamper therapeutic development, particularly with natural food-based molecules where binding targets remain undefined, limiting regulatory mechanism understanding and clinical application, while emerging combination therapies require further safety evaluation in long-term use

Wegovy 7.2 mg's Role in the Evolving Obesity Treatment Landscape

The obesity treatment landscape has undergone remarkable transformation over the past five years, primarily driven by the emergence of highly effective GLP-1 receptor agonists and novel combination therapies. Network meta-analyses demonstrate that subcutaneous semaglutide 2.4 mg consistently achieves 11.5 to 12.5 kg of weight loss across multiple trials, while tirzepatide, a dual GLP-1/GIP receptor co-agonist, has achieved unprecedented weight loss of up to 22.5% in non-diabetic individuals with obesity—results comparable to bariatric surgery outcomes. The recent introduction of mazdutide, a dual GLP-1 and glucagon receptor agonist, has shown promising results with 11.7% mean weight reduction at 12 weeks in Chinese adults, further expanding the therapeutic armamentarium.

Beyond pharmacological advances, the treatment paradigm has evolved to encompass more comprehensive, multimodal approaches with enhanced recognition of obesity as a chronic disease requiring systematic management. Primary care diagnosis recording has emerged as a critical intervention, with patients receiving formal obesity diagnoses being 32% more likely to achieve weight loss and 2.6 times more likely to visit dietitians. Shared medical appointments have demonstrated superior outcomes compared to individual consultations, with SMA participants achieving 4.2%, 5.2%, and 3.8% weight loss at 6, 12, and 24 months respectively, versus significantly lower losses in conventional care groups. Additionally, 49.8% of SMA patients received anti-obesity medication prescriptions compared to only 12.3% in standard care.

The landscape has also expanded to address previously underserved populations, with liraglutide receiving FDA approval in 2020 for pediatric use in children aged 12-17 years with obesity, marking the first GLP-1 RA approved for this indication. Long-term intensive multicomponent behavioral interventions with parental involvement have demonstrated enhanced effectiveness in pediatric populations. Furthermore, the field has recognized broader health implications, with real-world data showing that each 1% BMI reduction correlates with reduced obesity-related cancer risk at 3, 5, and 10-year intervals, while cardiovascular outcome trials are increasingly demonstrating superiority in primary cardiovascular endpoints compared to placebo across lifestyle interventions, bariatric surgery, and pharmacotherapy.

Wegovy 7.2 mg: A New Benchmark for Obesity Treatment in Europe

The European Medicines Agency's positive opinion for Wegovy 7.2 mg marks a pivotal moment in the pharmacological management of obesity, signaling the arrival of an even more potent therapeutic option. This higher-dose semaglutide, already available in the US and UK, demonstrated remarkable efficacy in the STEP UP trials, achieving a mean bodyweight reduction of 20.7% and enabling approximately one-third of participants to achieve 25% or greater weight loss. This significantly surpasses the outcomes observed with the 2.4 mg dose and placebo, establishing a new benchmark for weight loss in adults with obesity without diabetes.

For Novo Nordisk, this development solidifies its leadership in the burgeoning GLP-1 agonist market. By offering a differentiated, higher-efficacy product, the company can cater to a broader spectrum of patients, including those who may not achieve their therapeutic goals with lower doses. This strategic move not only extends the lifecycle of the semaglutide franchise but also intensifies competitive pressure on other players in the obesity space, who will now need to demonstrate comparable or superior efficacy.

However, the path to market dominance is not without its considerations. While the overall risk-benefit profile remains favorable, the 7.2 mg dose is associated with a higher incidence of gastrointestinal adverse events and dysaesthesia compared to the 2.4 mg dose. These tolerability concerns could influence patient adherence and persistence, necessitating robust patient education and support strategies. Furthermore, the anticipated Q3 2026 EU launch provides a substantial window for competitors to introduce new therapies or strengthen their market positions. Payer acceptance and reimbursement for a higher-dose, potentially higher-cost treatment will also be critical factors influencing its market penetration and uptake across diverse European healthcare systems. The successful integration of this new dose will depend on navigating these clinical and market dynamics effectively.